Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Cyclofenil is a synthetic, non-steroidal selective estrogen receptor modulator (SERM) that acts as a mixed agonist and antagonist of estrogen receptors. It was primarily used as a gonadotropin stimulant or ovulation inducer in women with anovulatory infertility and for menopausal hormone therapy. Cyclofenil works by blocking the actions of estrogens in the pituitary gland and hypothalamus, thereby disinhibiting the release of gonadotropins such as luteinizing hormone (LH) and follicle-stimulating hormone (FSH), which can stimulate ovulation. In men, it can increase testosterone levels due to its progonadotropic effects but is not effective for this purpose in women. Cyclofenil binds to estrogen receptor beta (ERβ) and demonstrates tissue-dependent agonism or antagonism. The drug was withdrawn from most markets due to a high risk of hepatotoxicity[1][4][7].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on cyclofenil.